Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bozitinib - Apollomics/Beijing Pearl Biotechnology

Drug Profile

Bozitinib - Apollomics/Beijing Pearl Biotechnology

Alternative Names: APL-101; Bozitinib - Beijing Pearl Biotechnology/CBT Pharmaceuticals; CBI-3103; CBT-101; PLB-1001

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crown Bioscience
  • Developer Apollomics; Beijing Pearl Biotechnology; Crown Bioscience
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer; Renal cell carcinoma
  • Phase I Solid tumours
  • No development reported Glioma; Non-small cell lung cancer

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Glioma(Second-line therapy or greater) in China (PO)
  • 01 Oct 2019 Beijing Pearl Biotechnology completes a phase I trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in China (PO) (NCT02896231)
  • 28 May 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top